Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The entity **non transabdominal plane block-Icahn School of Medicine at Mount Sinai-postoperative pain** refers to the placebo control arm of a Phase 2 clinical trial (NCT02007096) conducted by the Icahn School of Medicine at Mount Sinai. This intervention involves the administration of a saline injection (0.9% sodium chloride) in six different abdominal locations during laparoscopic ventral hernia repair. The study was designed to evaluate whether a Transabdominal Plane (TAP) block using bupivacaine could significantly reduce postoperative pain and opioid use compared to this non-active control. As a placebo, the saline injection does not contain active analgesic agents and serves to establish a baseline for comparing the efficacy of regional anesthesia techniques in the early postoperative period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on non transabdominal plane block-Icahn School of Medicine at Mount Sinai-postoperative pain.